Literature DB >> 31721050

Contribution of Fc fragment of monoclonal antibodies to tetanus toxin neutralization.

Somayeh Ghotloo1, Mohammad Mehdi Amiri1, Jalal Khoshnoodi1, Ebrahim Abbasi2, Mahmood Jeddi-Tehrani3, Forough Golsaz-Shirazi1, Fazel Shokri4,5.   

Abstract

BACKGROUND: Monoclonal antibodies (MAbs) against neurotoxin of Clostridium tetani are considered as a novel source of immunoglobulins for passive immunotherapy of tetanus. Toxin neutralization is classically attributed to the Fab and F(ab')2 fragments of antibodies. Herein, we generated Fab and F(ab')2 fragments of three toxin neutralizing mouse MAbs and compared their neutralizing activities to those of their intact molecules.
METHODS: Fab and F (ab')2 fragments of the antibodies were generated by papain and pepsin digestions, respectively, and their toxin neutralizing activities were compared with those of the intact antibodies in an in vivo toxin neutralization assay.
RESULTS: While low doses of the intact MAbs were able to fully protect the mice against tetanus toxin, none of the mice which received Fab or F(ab')2 fragments survived until day 14, even at the highest administered dose. All mice receiving human polyclonal anti-tetanus immunoglobulin or their fragments were fully protected.
CONCLUSION: Reduction in toxin neutralization activities of Fab and F(ab')2 fragments of our MAbs seems to be influenced by their Fc regions. Steric hindrance of the Fc region on the receptor-binding site of the toxin may explain the stronger neutralization of the toxin by the intact MAbs in comparison to their fragments.

Entities:  

Keywords:  F(ab′)2; Fab; Monoclonal antibody; Tetanus toxin; Toxin neutralization

Mesh:

Substances:

Year:  2019        PMID: 31721050     DOI: 10.1007/s12640-019-00124-9

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  28 in total

1.  Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies.

Authors:  Mehdi Yousefi; Roya Khosravi-Eghbal; Ahmad Reza Mahmoudi; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Fazel Shokri
Journal:  Hum Vaccin Immunother       Date:  2013-10-14       Impact factor: 3.452

2.  Characterization of neutralizing monoclonal antibodies directed against tetanus toxin fragment C.

Authors:  Mehdi Yousefi; Fathollah Tahmasebi; Vahid Younesi; Alireza Razavi; Jalal Khoshnoodi; Ali Ahmad Bayat; Ebrahim Abbasi; Hodjatallah Rabbani; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  J Immunotoxicol       Date:  2013-02-01       Impact factor: 3.000

3.  Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells.

Authors:  P Marxen; U Fuhrmann; H Bigalke
Journal:  Toxicon       Date:  1989       Impact factor: 3.033

Review 4.  Maternal and neonatal tetanus.

Authors:  C Louise Thwaites; Nicholas J Beeching; Charles R Newton
Journal:  Lancet       Date:  2014-08-19       Impact factor: 79.321

5.  Optimal conditions for the preparation of Fab and F(ab')2 fragments from monoclonal IgG of different rat IgG subclasses.

Authors:  J Rousseaux; R Rousseaux-Prévost; H Bazin
Journal:  J Immunol Methods       Date:  1983-11-11       Impact factor: 2.303

6.  Comparison between IgG and F(ab')(2) polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions.

Authors:  G León; M Monge; E Rojas; B Lomonte; J M Gutiérrez
Journal:  Toxicon       Date:  2001-06       Impact factor: 3.033

7.  The structures of the H(C) fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding.

Authors:  P Emsley; C Fotinou; I Black; N F Fairweather; I G Charles; C Watts; E Hewitt; N W Isaacs
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

8.  Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding.

Authors:  Nathan Scott; Omar Qazi; Michael J Wright; Neil F Fairweather; Mahendra P Deonarain
Journal:  Mol Immunol       Date:  2010-04-22       Impact factor: 4.407

9.  Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.

Authors:  D G Covell; J Barbet; O D Holton; C D Black; R J Parker; J N Weinstein
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

10.  Role of Fc in antibody-mediated protection from ricin toxin.

Authors:  Seth H Pincus; Anushka Das; Kejing Song; Grace A Maresh; Miriam Corti; Jody Berry
Journal:  Toxins (Basel)       Date:  2014-05-07       Impact factor: 4.546

View more
  2 in total

1.  Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice.

Authors:  Marco Pirazzini; Alessandro Grinzato; Davide Corti; Sonia Barbieri; Oneda Leka; Francesca Vallese; Marika Tonellato; Chiara Silacci-Fregni; Luca Piccoli; Eaazhisai Kandiah; Giampietro Schiavo; Giuseppe Zanotti; Antonio Lanzavecchia; Cesare Montecucco
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

Review 2.  Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design.

Authors:  Somayeh Ghotloo; Faezeh Maghsood; Forough Golsaz-Shirazi; Mohammad Mehdi Amiri; Christiane Moog; Fazel Shokri
Journal:  Rev Med Virol       Date:  2022-04-08       Impact factor: 11.043

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.